Galectin Therapeutics (GALT) Payables (2010 - 2026)

Galectin Therapeutics' Payables history runs 17 years deep, the most recent figure standing at $3.1 million for Q1 2026.

• In Q1 2026, Payables fell 54.36% year-over-year to $3.1 million; the TTM figure through Mar 2026 stood at $3.1 million (down 54.36% YoY), while the FY2025 annual figure was $3.3 million, down 45.66% from the prior year.
• Payables for Q1 2026 stood at $3.1 million, down from $3.3 million in the prior quarter.
• The five-year high for Payables was $9.1 million in Q3 2025, with the low at $1.9 million in Q1 2022.
• The 5-year median for Payables is $3.3 million (2025), against an average of $4.1 million.
• The sharpest annual moves came in 2022 and 2026: Payables soared 398.95% in 2022, then tumbled 54.36% in 2026.
• Galectin Therapeutics' Payables stood at $4.0 million in 2022, then surged by 64.24% to $6.5 million in 2023, then dropped by 6.25% to $6.1 million in 2024, then slumped by 45.66% to $3.3 million in 2025, then retreated by 5.65% to $3.1 million in 2026.
• Business Quant data shows GALT's Payables at $3.1 million in Q1 2026, $3.3 million in Q4 2025, and $9.1 million in Q3 2025.